Can Marinol (dronabinol) be used to stimulate appetite in patients with weight loss due to chronic illness?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Marinol for Appetite Stimulation

Marinol (dronabinol) can be used for appetite stimulation in AIDS-related anorexia with weight loss, where it demonstrates statistically significant improvement in appetite, but it should NOT be used for cancer cachexia due to lack of efficacy and potential detrimental effects on quality of life.

FDA-Approved Indication and Evidence

Marinol is FDA-approved specifically for AIDS-related anorexia with weight loss 1. The pivotal trial demonstrated:

  • Statistically significant appetite improvement at weeks 4 and 6 compared to placebo (visual analog scale)
  • Trends toward improved body weight, mood, and decreased nausea
  • Sustained appetite improvement in open-label extension 1

Dosing for appetite stimulation:

  • Start: 2.5 mg twice daily (1 hour before lunch and dinner)
  • If side effects occur (18% experience feeling high, dizziness, confusion, somnolence): reduce to 2.5 mg once daily at supper or bedtime
  • Maximum: 10 mg twice daily 1

Cancer Cachexia: Do NOT Use

The 2024 ASCO Cannabis Guideline explicitly found that cannabinoids, including dronabinol, do NOT improve appetite or weight in cancer patients and actually have a small detrimental effect on quality of life (standardized mean difference -0.25,95% CI -0.43 to -0.07) 2.

The 2020 ASCO Cancer Cachexia Guideline does not recommend dronabinol for cancer cachexia management 3. Instead:

  • First-line: Megestrol acetate (800 mg/day) - proven superior to dronabinol 2.5 mg twice daily 4
  • Short-term only: Corticosteroids for patients with life expectancy of weeks to months 3

Clinical Context and Limitations

Hospitalized patients: Recent evidence (2023,2019) shows dronabinol has limited efficacy for improving appetite and meal intake in the inpatient setting, with no significant weight change 5, 6. The 2019 study showed only numerical (not statistically significant) improvements in meal intake 6.

Older adults in long-term care: A 2007 pilot study showed mixed results - 53.5% gained weight, but those who lost weight had 64% mortality versus 26% in weight gainers, suggesting failure to respond may indicate poor prognosis 7.

Key Safety Considerations

Neuropsychiatric effects are dose-limiting:

  • Euphoria, drowsiness, dizziness, vertigo, hallucinations
  • Sedation (19%), disorientation (3%) in clinical trials 2
  • Elderly patients at higher risk for cognitive impairment 1
  • Additive CNS depression with alcohol, benzodiazepines, barbiturates 1

Drug interactions:

  • Increases pentobarbital half-life by 4 hours
  • 2-3 fold higher exposure in patients with CYP2C9 genetic variants 1

Clinical Algorithm

For AIDS-related anorexia with weight loss:

  1. Start dronabinol 2.5 mg twice daily (before lunch and dinner)
  2. Monitor for neuropsychiatric side effects at 1-2 weeks
  3. If intolerable side effects: reduce to 2.5 mg once daily at bedtime
  4. If inadequate response and well-tolerated: may increase gradually
  5. Assess appetite improvement at 4-6 weeks

For cancer-related anorexia/cachexia:

  1. Do NOT use dronabinol - evidence shows harm to quality of life 2
  2. Use megestrol acetate 800 mg/day instead 3, 4
  3. Address nutrition impact symptoms (nausea, pain, dysgeusia) 3

For hospitalized patients or other chronic illnesses:

  • Evidence insufficient to recommend routine use 5, 6
  • Consider only after addressing reversible causes of poor intake
  • Set realistic expectations - weight gain unlikely during acute hospitalization

Critical Pitfall

The most common error is using dronabinol for cancer cachexia based on its FDA approval for "anorexia with weight loss." This is specifically approved only for AIDS patients, and recent high-quality guidelines explicitly recommend against its use in cancer due to lack of efficacy and potential harm to quality of life 2, 3.

References

3
Guideline

management of cancer cachexia: asco guideline.

Journal of Clinical Oncology, 2020

5
Research

A review of the efficacy of appetite stimulating medications in hospitalized adults.

Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition, 2023

Related Questions

Is Marinol (dronabinol) appropriate as an appetite stimulant for an older adult with reduced appetite?
What appetite‑stimulating medications can I prescribe as a family primary care physician for an adult patient with severe weight loss (down to 80 lb) and loss of appetite?
Which antihistamines are effective for appetite stimulation, including recommended dosing and safety considerations?
What appetite stimulant can be used in a patient with constipation?
What appetite stimulant medication is appropriate for an elderly nursing‑home resident with poor appetite, considering contraindications such as active thromboembolic disease, uncontrolled diabetes, severe liver dysfunction, or recent gastrointestinal bleeding?
What is the appropriate management of a hemodynamically unstable patient with atrial flutter at a ventricular rate of 180 beats per minute?
What oral diet should be recommended for a patient with ongoing lymphorrhea?
How does Thorazine (chlorpromazine) work?
What is the appropriate dosing regimen for pravastatin, including dose adjustments for patients with severe renal impairment, hepatic disease, and elderly individuals?
What is the appropriate dosing regimen for Thorazine (chlorpromazine)?
Should the patient continue the current romiplostim (Nplate) dose of 8 µg/kg given his platelet counts of 92 ×10⁹/L today and 121 ×10⁹/L last week?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.